Importantly, the WT134‐51 helper peptide, which can be utilized for all MHC class II types [16], significantly contributes to tumor eradication not only through CD4+ Th1 cells, but also WT1-specific CD8+ CTLs in antitumor immunity [23]. This evidence concerns the gene CD8A and neoplasm.